Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01702896 · ClinicalTrials.gov registry record · Phase 2
Interleukin-2 in Metastatic Melanoma
A Phase 2 study, sponsored by Western Regional Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01702896: Clinical Trial Phase 2 study, sponsored by Western Regional Medical Center.
NCT01702896 is a Phase 2 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01702896, a Phase 2 study, was terminated before completion, sponsored by Western Regional Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
To determine whether Interleukin-2 at the dose and schedule will help to increase tumor shrinkage
Interventions
- DRUG Interleukin-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-09 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01702896
The ClinicalTrials.gov registry entry for NCT01702896 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Western Regional Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interleukin-2 is the first listed.
NCT01702896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01702896 about?
NCT01702896 is a clinical study titled "Interleukin-2 in Metastatic Melanoma". To determine whether Interleukin-2 at the dose and schedule will help to increase tumor shrinkage
What is the current status of trial NCT01702896?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2012-09. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01702896?
The interventions under investigation include: Interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT01702896?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.